Session » Antiphospholipid Syndrome - Poster II
-
Abstract Number: 2086
Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients
-
Abstract Number: 2087
A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome
-
Abstract Number: 2088
Rituximab Use in Pediatric Lupus Anticoagulant Hypoprothrombinemia Syndrome – Report of Three Cases and Review of the Literature
-
Abstract Number: 2089
Deviation of T and B Cell Subset and Its Association with Single Nucleotide Polymorphisms in Patients with Antiphospholipid Syndrome
-
Abstract Number: 2090
Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing
-
Abstract Number: 2091
Antiphospholipid Syndrome Patients’ Time within Therapeutic Range of International Normalized Ratio (INR)
-
Abstract Number: 2092
Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.
-
Abstract Number: 2093
Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment
-
Abstract Number: 2094
Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System
-
Abstract Number: 2095
Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome
-
Abstract Number: 2096
Venous Antiphospholipid Syndrome: Is the Unprovoked Nature of the 1st Thrombosis Associated with Clinical or Biological Features?
-
Abstract Number: 2097
Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients
-
Abstract Number: 2098
Non-Criteria Anti-Phospholipid Antibodies in SLE Patients
-
Abstract Number: 2099
Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome
-
Abstract Number: 2100
Pharmaceutical Disruption of B2GPI CXCL4 Complex Using Computationally Designed Oligopeptides